Zacks Research Analysts Increase Earnings Estimates for PBYI

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Research analysts at Zacks Research upped their Q4 2025 EPS estimates for Puma Biotechnology in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.16 per share for the quarter, up from their prior forecast of $0.13. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.01 EPS and Q3 2026 earnings at $0.11 EPS.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. During the same period in the previous year, the firm earned $0.12 EPS.

PBYI has been the topic of a number of other reports. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd.

Puma Biotechnology Stock Down 2.0 %

Shares of PBYI stock opened at $2.96 on Friday. Puma Biotechnology has a 1 year low of $2.22 and a 1 year high of $7.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The business’s fifty day moving average is $3.06 and its 200-day moving average is $2.99. The stock has a market cap of $145.30 million, a PE ratio of 6.17 and a beta of 1.10.

Hedge Funds Weigh In On Puma Biotechnology

A number of large investors have recently made changes to their positions in PBYI. Gateway Wealth Partners LLC acquired a new position in Puma Biotechnology in the 4th quarter valued at approximately $31,000. SG Americas Securities LLC acquired a new position in shares of Puma Biotechnology in the third quarter worth $34,000. Franklin Resources Inc. acquired a new position in shares of Puma Biotechnology in the third quarter worth $41,000. Dynamic Technology Lab Private Ltd acquired a new stake in Puma Biotechnology during the third quarter valued at $44,000. Finally, Patriot Financial Group Insurance Agency LLC increased its position in Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Transactions at Puma Biotechnology

In related news, CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares in the company, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now directly owns 108,951 shares in the company, valued at $343,195.65. This represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.